MedPage Today -- ORLANDO -- The investigational platelet aggregation inhibitor ticagrelor appeared to produce better outcomes in patients with high-risk, acute coronary syndromes than clopidogrel (Plavix), investigators reported here in a finding that mirrored results of an earlier, larger study.
